NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether Viatris and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial ...Full story available on Benzinga.com
Viatris is a Pennsylvania-based pharmaceutical company that researches and develops generic and biosimilar drugs for the treatment of infectious diseases.